Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

5.7K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.7K
DNA-only Transposons02:57

DNA-only Transposons

17.5K
DNA-only transposons are called autonomous transposons since they code for the enzyme transposase that is required for the transposition mechanism. Insertion of transposons can alter gene functions in multiple ways. They can mutate the gene, alter gene expression by introducing a novel promoter or insulator sequence, introduce new splice sites, and change the mRNA transcripts produced, or remodel chromatin structure.
The donor site from where the transposon is excised is either degraded or...
17.5K
Overview of Transposition and Recombination02:13

Overview of Transposition and Recombination

19.3K
Transposons make up a significant part of genomes of various organisms. Therefore, it is believed that transposition played a major evolutionary role in speciation by changing genome sizes and modifying gene expression patterns. For example, in bacteria, transposition can lead to conferring antibiotic resistance. Movement of transposable elements within the genetic pool of pathogenic bacteria can aid in transfer of antibiotic-resistant genetic elements. In eukaryotes, transposons can carry out...
19.3K
What is Cell Signaling?02:03

What is Cell Signaling?

130.4K
Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
130.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mast cells fuel squamous cell carcinoma through a targetable MRGPRX2-IL-17A axis.

The Journal of investigative dermatology·2026
Same author

Chronic kidney disease and itch.

Itch (Philadelphia, Pa.)·2025
Same author

A review of catechins and their use in atopic dermatitis.

Itch (Philadelphia, Pa.)·2025
Same author

Cryoneurolysis with Injectable Ice Slurry Modulates Mechanical Skin Pain.

The Journal of investigative dermatology·2022
Same author

Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb.

The Journal of allergy and clinical immunology·2022
Same author

Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide.

Frontiers in immunology·2020
Same journal

Reducing plastic waste in skin-model research: Sustainable packaging as a practical first step.

The Journal of investigative dermatology·2026
Same journal

Modern serum proteomics in precision medicine: Toward disease stratification and predictive, proactive treatment strategies.

The Journal of investigative dermatology·2026
Same journal

An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.

The Journal of investigative dermatology·2026
Same journal

Residual CSB activity explains mild UV-sensitive syndrome phenotype caused by CSB mutations.

The Journal of investigative dermatology·2026
Same journal

Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.

The Journal of investigative dermatology·2026
Same journal

Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris.

The Journal of investigative dermatology·2026
See all related articles

Related Experiment Video

Updated: Feb 2, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K

Targeting PAR2 with Pepducins.

Melissa Sheridan Lee1, Ethan A Lerner1

  • 1Massachusetts General Hospital, Boston, Massachusetts, USA.

The Journal of Investigative Dermatology
|November 26, 2018
PubMed
Summary
This summary is machine-generated.

A novel pepducin peptide effectively modulates protease-activated receptor 2 (PAR2) activity, offering a new therapeutic strategy for itch, inflammation, and atopic dermatitis by blocking G protein coupling.

More Related Videos

Author Spotlight: Navigating Challenges and Innovations in Muscle Stem Cell Studies
07:09

Author Spotlight: Navigating Challenges and Innovations in Muscle Stem Cell Studies

Published on: March 1, 2024

1.4K
Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
11:37

Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution

Published on: February 26, 2019

10.3K

Related Experiment Videos

Last Updated: Feb 2, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.0K
Author Spotlight: Navigating Challenges and Innovations in Muscle Stem Cell Studies
07:09

Author Spotlight: Navigating Challenges and Innovations in Muscle Stem Cell Studies

Published on: March 1, 2024

1.4K
Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
11:37

Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution

Published on: February 26, 2019

10.3K

Area of Science:

  • Dermatology
  • Molecular Biology
  • Pharmacology

Background:

  • Protease-activated receptor 2 (PAR2) activation is implicated in itch, inflammation, and atopic dermatitis.
  • Targeting PAR2 presents significant therapeutic challenges.
  • Existing strategies for modulating PAR2 activity are limited.

Purpose of the Study:

  • To develop a novel therapeutic approach for conditions involving PAR2.
  • To investigate the efficacy of a cell-penetrating peptide (pepducin) in modulating PAR2.
  • To assess the pepducin's impact on itch, inflammation, and atopic dermatitis models.

Main Methods:

  • Development of a cell-penetrating peptide (pepducin) designed to inhibit PAR2.
  • Administration of the pepducin in established models of itch, inflammation, and atopic dermatitis.
  • Evaluation of PAR2 signaling pathways and downstream effects.

Main Results:

  • The developed pepducin successfully prevented PAR2 from coupling to G proteins.
  • The pepducin demonstrated significant modulation of itch and inflammation in tested models.
  • The therapeutic potential of the pepducin was confirmed in atopic dermatitis models.

Conclusions:

  • Pepducins represent a promising new class of therapeutics for PAR2-mediated conditions.
  • This study validates a novel mechanism for targeting PAR2, bypassing previous challenges.
  • The findings suggest a viable therapeutic avenue for managing atopic dermatitis and associated symptoms.